Two Good Reasons To Buy GlaxoSmithKline plc Today

The current headwinds facing GlaxoSmithKline plc (LON:GSK) have created a buying opportunity, argues Roland Head.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Yesterday’s news that GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) had sold Ribena and Lucozade to Japanese drinks giant Suntory Beverage & Food Ltd was bound to make headlines, as journalists picked up on the sale of yet more British food and drink brands to foreign companies.

Personally, I’m more interested in Glaxo’s prospects as a pharmaceutical business, and I was pleased with the terms of the deal. The £1.35bn price tag is equivalent to 2.6 years’ sales, and is probably 10-15 times the annual profits generated by the drinks.

Despite this, the deal wasn’t enough to move Glaxo’s share price, which has fallen by 5% since June, thanks to two separate problems faced by the company. Sceptics are calling Glaxo a sell, but I reckon these two problems are simply a good buying opportunity.

China fiasco

China is expected to become the world’s second-largest market for pharmaceutical firms over the next decade. Its population of 1.3bn is enjoying rising incomes and a move to urbanised living, both of which will increase access to, and demand for, western-style healthcare.

Glaxo saw the opportunity in China, but if current allegations that the firm funded up to £320m of bribes to Chinese doctors are proved to be true, it appears to have grasped at it rather too eagerly.

Various media reports are suggesting that Glaxo may now withdraw from China to avoid a hefty fine, and allegations of corporate bribery, but I think this is simply a negotiating tactic. I don’t think that a withdrawal is in the interests of Glaxo or of the Chinese authorities, and expect a settlement.

Patent cliff?

As I write, Glaxo’s share price is down by around 3% on this morning’s opening price. The reason for this is that the US Food and Drugs Administration has unexpectedly issued guidance suggesting that it will licence generic replacements for Glaxo’s inhaler drug, Advair, which has global annual sales of $8bn.

Advair’s active ingredients are already out of patent, but the inhaler device with which it is delivered is protected until 2016, after which it now appears that Advair sales may fall, as cheaper generic competitors enter the market.

However, this needs to be seen in context. Glaxo’s product pipeline is seen by analysts as being much healthier than that of its UK peer AstraZeneca, and it has two full years before any generic replacements for Advair can hit the market.

Buying opportunity?

Glaxo’s 4.7% yield and growth potential make it a buy for me, and it’s worth noting that GlaxoSmithKline is also one of the eight biggest holdings of top UK fund manager Neil Woodford.

Mr. Woodford’s funds have delivered outstanding returns for his investors — if you’d invested £10,000 into Mr Woodford’s High Income fund in 1988, it would have been worth £193,000 at the end of 2012 — a 1,830% increase!

For access to an exclusive Fool report about all eight of Neil Woodford’s largest holdings, just click here. The report is free, but availability is limited.

> Roland owns shares in GlaxoSmithKline but does not own shares in any of the other companies mentioned in this article. The Motley Fool has recommended GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Down 23%! Should I buy more CrowdStrike shares for my Stocks and Shares ISA?

Sometimes bad news can be good news for long-term investors. But is that the case for CrowdStrike in relation to…

Read more »

Investing Articles

2 UK shares near 52-week lows I’m considering snapping up

These UK shares are loitering near, or at, 52-week lows. Are these prime opportunities for our writer to boost her…

Read more »

Investing Articles

Unilever: a passive income stock with potential for decades of dividend growth

Stephen Wright thinks Unilever can keep reducing its share count for years to come. And this should help make it…

Read more »

Middle-aged black male working at home desk
Investing Articles

Worried about retirement? I’d buy high-yield dividend shares to build wealth

The number of pensioners enduring poverty in the UK looks set to rise. Investing in dividend shares could help Britons…

Read more »

Investing For Beginners

2 boring but beautiful FTSE 100 stocks to add to my ISA

Jon Smith runs over a couple of FTSE 100 stocks that he really likes the look of, even though they…

Read more »

Investing Articles

Here’s how I could supercharge my wealth by snapping up the best dividend stocks!

This Fool explains how dividend stocks play a crucial part of her aspirations to build wealth, and details one pick…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Revenue up 10% and accelerated growth potential for this overlooked FTSE 250 company

Today's first-quarter update from this good-value FTSE 250 company keeps me keen on the stock as recovery and growth continues.

Read more »

Investing Articles

Here’s why I’m so bullish about the BT share price now

The BT share price shot up after FY results, and a couple of months on it's still up there. Might…

Read more »